Price Change to Note: Smith & Nephew plc (ADR) Sets 52 Week Low; Strong Momentum for Sellers

Price Change to Note: Smith & Nephew plc (ADR) Sets 52 Week Low; Strong Momentum for Sellers

The stock of Smith & Nephew plc (ADR) (NYSE:SNN) hit a new 52-week low and has $25.75 target or 5.00% below today’s $27.11 share price. The 8 months bearish chart indicates high risk for the $11.77B company. The 1-year low was reported on Nov, 14 by If the $25.75 price target is reached, the company will be worth $588.50 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 991,130 shares traded hands or 67.48% up from the average. Smith & Nephew plc (ADR) (NYSE:SNN) has declined 18.44% since April 12, 2016 and is downtrending. It has underperformed by 23.42% the S&P500.

Smith & Nephew plc (ADR) (NYSE:SNN) Ratings Coverage

Out of 7 analysts covering Smith & Nephew PLC (ADR) (NYSE:SNN), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. Smith & Nephew PLC (ADR) has been the topic of 7 analyst reports since October 29, 2015 according to StockzIntelligence Inc. On Thursday, October 6 the stock rating was downgraded by Berenberg to “Hold”. The stock of Smith & Nephew plc (ADR) (NYSE:SNN) earned “Neutral” rating by UBS on Thursday, February 11. The firm earned “Equal-Weight” rating on Wednesday, August 10 by Barclays Capital. The firm earned “Neutral” rating on Wednesday, November 4 by Sterne Agee CRT. The rating was upgraded by Jefferies to “Buy” on Monday, May 9.

According to Zacks Investment Research, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world”

More important recent Smith & Nephew plc (ADR) (NYSE:SNN) news were published by: which released: “Healthcare Stocks To Watch: Smith & Nephew (SNN), Aethlon Medical (AEMD …” on November 26, 2014, also published article titled: “Sanofi SA (SNY) Continues Search For Head; Smith & Nephew (SNN) CEO Out Of The …”, published: “Smith & Nephew Continues To Impress” on July 25, 2016. More interesting news about Smith & Nephew plc (ADR) (NYSE:SNN) was released by: and their article: “Stryker Corporation (SYK) Announces $2 Billion Share Buyback Program, Quelling …” with publication date: March 04, 2015.

SNN Company Profile

Smith & Nephew plc, incorporated on February 17, 1937, is a medical technology company. The Firm is engaged in developing, manufacturing, marketing and selling medical devices and services. The Firm offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives. The Firm offers its products to healthcare professionals in over 100 countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment